ライフサイエンスコーパス: antitumor activity

1 t (TME) contains ROS, which suppress NK cell antitumor activity.

2 nd PGE(2) are essential regulators of T cell antitumor activity.

3 astoma and investigated the mechanism of its antitumor activity.

4 ect immune modulation, indispensable for its antitumor activity.

5 th APCs can enhance their ability to mediate antitumor activity.

6 as a novel therapeutic strategy to stimulate antitumor activity.

7 ironment in promoting NK cell maturation and antitumor activity.

8 a, an essential molecule for T-cell-mediated antitumor activity.

9 , which correlated with the earlier observed antitumor activity.

10 potent Ag-specific CD8 T cell responses and antitumor activity.

11 s holds strong potential for improving their antitumor activity.

12 nducing chemotherapy resulted in synergistic antitumor activity.

13 ith SRC plus AKT inhibitors has even greater antitumor activity.

14 exhibits superior selectivity, potency, and antitumor activity.

15 gin, a cytotoxic natural product with potent antitumor activity.

16 rols CD8(+) T memory precursor formation and antitumor activity.

17 an anti-class II MHC antibody abrogated its antitumor activity.

18 tabolism, acceptable toxicity, and promising antitumor activity.

19 1 antibody, confirming a role for T cells in antitumor activity.

20 ombine with immuno-oncology drugs to enhance antitumor activity.

21 as a manageable safety profile and promising antitumor activity.

22 CAR) may reduce the side effects and augment antitumor activity.

23 in-like (KIR) receptors and interrupts their antitumor activity.

24 ts of the PLN carrier, but also had moderate antitumor activity.

25 sessed for toxicities, pharmacokinetics, and antitumor activity.

26 l without affecting CD19-specific CAR T-cell antitumor activity.

27 potent microtubule depolymerizing agent with antitumor activity.

28 ly on significant in vivo expansion to exert antitumor activity.

29 r is a novel and safe therapeutic with broad antitumor activity.

30 iations between hypoxia, neoangiogenesis and antitumor activity.

31 /FGFR interaction and endowed with promising antitumor activity.

32 Selenosemicarbazones show marked antitumor activity.

33 ns, as well as for its antiproliferative and antitumor activity.

34 wed no significant effect on B7H3 CAR T-cell antitumor activity.

35 equiring dose deescalation, with only modest antitumor activity.

36 d selectivity properties, and potent in vivo antitumor activity.

37 ntadine demonstrated remarkable single-agent antitumor activity.

38 agonist properties, including potent in vivo antitumor activity.

39 AR-T cells abolished in vivo persistence and antitumor activity.

40 in potentiating immunotherapy strategies and antitumor activity.

41 ks multiple oncogenic pathways, resulting in antitumor activity.

42 ofur's mysterious 5-fluorouracil-independent antitumor activity.

43 cytokine can promote tumor growth, but also antitumor activities.

44 potent PSD inhibitors with antimicrobial or antitumor activities.

45 -1), devoid of the gamma(1)34.5 gene, exerts antitumor activities.

46 w pathway dependencies and drugs with potent antitumor activities.

47 an TAMs immune suppression of NK- and T-cell antitumor activities.

48 ating agent with immunomodulatory and direct antitumor activities.

49 e of compounds with potent antimicrobial and antitumor activities.

50 hibitors with PD-1 blockade therapy improves antitumor activity(4-6), which may provide additional tr

51 Loss of donor-mediated immune antitumor activity after allogeneic hematopoietic stem-c

52 sults provide a proof of concept of systemic antitumor activity after intratumoral CD40 triggering wi

53 human melanoma WM115 cell line have superior antitumor activity after photothermal ablation of the tu

54 e BTDs were characterized in vitro for their antitumor activity against A549, PC-3, and HCT-116 cance

55 is the first regimen to demonstrate improved antitumor activity against BMs in patients with HER2-pos

56 ulture condition (T9 CAR-T) have an enhanced antitumor activity against established tumors.

57 mouse xenografts revealed that 6OTD exhibits antitumor activity against glioblastoma.

58 and metabolic stability and 39 times higher antitumor activity against hormone-resistant prostate ca

59 nsus androgen response element half-site has antitumor activity against hormone-sensitive prostate ca

60 rtunity in colorectal cancer and may exhibit antitumor activity against other tumor types.

61 the ability of naive OT-1 T cells to develop antitumor activity against ovalbumin-expressing melanoma

62 nstrated a safety therapy profile with broad antitumor activity against solid and hematological malig

63 nger follow-up, NIVO3 demonstrated sustained antitumor activity alone and in combination with ipilimu

64 e results in impaired NK cell maturation and antitumor activity, although underlying mechanisms are l

65 hich suggests that these agents have similar antitumor activity among patients with advanced NETs.

66 e are macrocyclic peptides showing promising antitumor activities and usually containing the highly u

67 BV represents a promising option, with high antitumor activity and a manageable safety profile.

68 fies an optimal cell dose with highly potent antitumor activity and a tolerable adverse effect profil

69 embrolizumab exhibited clinically meaningful antitumor activity and an acceptable safety profile in r

70 may serve as a novel platform to improve the antitumor activity and clinical efficacy of therapeutic

71 cervical cancer, pembrolizumab demonstrated antitumor activity and exhibited a safety profile consis

72 HASPIN inhibition has direct antitumor activity and induces a favorable immune microe

73 On the other hand, NSPD has antitumor activity and is found in some species of plant

74 Here, we study the antitumor activity and mechanism of action of a nonrepli

75 adjust their levels postinfusion, maximizing antitumor activity and minimizing toxicity.

76 -containing) CAR-T cells resulted in limited antitumor activity and persistence.

77 cted increasing interest for their promising antitumor activity and potential utilization in the disc

78 etorolac and resolvins exhibited synergistic antitumor activity and prevented surgery- or chemotherap

79 Although they can paradoxically exert antitumor activity and prime protective immunity, the pa

80 administered OxLys-SNAs exhibit significant antitumor activity and prolonged survival relative to al

81 The antitumor activity and safety of crizotinib were assesse

82 TLR pathway inhibitor could provide superior antitumor activity and should be investigated in clinica

83 AhR inhibitors exert significant antitumor activity and synergize with anti-PD-L1 antibod

84 mily member specificity profiles for optimal antitumor activity and tolerability.

85 pharmacologic strategies for regulating the antitumor activity and toxicity of AZA and related drugs

86 rating this Bicycle also demonstrated potent antitumor activity and was very well tolerated when comp

87 rapy demonstrated manageable safety, notable antitumor activity, and durable responses with promising

88 daptive immune responses, promote lymphocyte antitumor activity, and prevent tumor immune evasion.

89 etic restoration or ectopic expression shows antitumor activity, and synergizes with anti-PD-1, notab

90 wever, the critical substrates mediating its antitumor activity are not fully defined.

91 mRNA (TriMixDC-MEL) are immunogenic and have antitumor activity as a monotherapy in patients with pre

92 Blinatumomab has shown potent antitumor activity as a single agent, particularly for a

93 BET proteins in tumors and exhibited strong antitumor activities at well-tolerated dosing schedules.

94 Antitumor activity at doses between 2.25 and 2.8 mg/kg o

95 l is as efficacious as melphalan, displaying antitumor activity at doses corresponding to only a frac

96 and STAT3 signaling, and exerts synergistic antitumor activity both in vitro and in vivo, with or wi

97 peutics metformin and phenformin, have shown antitumor activity both in vitro and in vivo.

98 t, Ctn(15-34), retains the antimicrobial and antitumor activities but is less toxic to healthy cells

99 ent protein kinase inhibitors with promising antitumor activity but suboptimal aqueous solubility, co

100 models confirmed differences in single-agent antitumor activity, but also showed potential for effect

101 yrin micelles (SN-NPM) enhanced the in vitro antitumor activity by 78 and 350 times over single treat

102 mulating factor (G-CSF) enhanced RT-mediated antitumor activity by activating RT-Ns.

103 isolated from Aglaia genus plants, exhibits antitumor activity by clamping eukaryotic translation in

104 es capable of activating p38 MAPK lose their antitumor activity by deleting B7-H1(+) tumor-reactive C

105 ved antifungal drug, has exhibited promising antitumor activity by down-regulating the expression of

106 phorylation of PTPN12 by CDK2 discharged its antitumor activity by down-regulation of its inhibitory

107 cgammaR-independent agonists with remarkable antitumor activity by isotype switching to hIgG2.

108 potential therapeutic target for stimulating antitumor activity by macrophages.

109 Remarkable antitumor activity by means of objective radiologic resp

110 trate that SIRPalpha blockade induces potent antitumor activity by targeting multiple myeloid cell su

111 these results demonstrate that JA exerts its antitumor activity by targeting SF3B1 and SF3B3 in addit

112 Pembrolizumab demonstrated effective antitumor activity; clinically meaningful, durable respo

113 607) or anti-PD-1 mAb therapy showed partial antitumor activity, combined treatment of BMS-777607 wit

114 y, nonblocking anti-PD-1 Abs have equivalent antitumor activity compared with blocker Abs in two mous

115 o and had enhanced proliferative and in vivo antitumor activity compared with FMC63 CAR T cells.

116 une checkpoint inhibitors has shown enhanced antitumor activity compared with monotherapy in tumor ty

117 g CAd-VECPDL1 with HER2.CAR T cells enhanced antitumor activity compared with treatment with either H

118 and upon activation while maintaining their antitumor activity despite high H2O2 levels.

119 in human cells, suggests that the selective antitumor activity displayed by OPA may be due to altere

120 nd short range of the alpha-particles induce antitumor activity, driven by the induction of complex D

121 N) and azacitidine (AZA) possess significant antitumor activity effect in AML.

122 As a result, HR is inhibited and antitumor activity enhanced in otherwise HR-proficient s

123 ary objectives included pharmacokinetics and antitumor activity; exploratory objectives included phar

124 dels in nude mice, demonstrating synergistic antitumor activity for the ATRi combination at doses dem

125 ne was limited despite a substantial initial antitumor activity found in the primary tumor setting.

126 The antitumor activity from Mertk inhibition was abrogated b

127 parib and anti-PD-1 demonstrated synergistic antitumor activities in both BRCA-proficient and BRCA-de

128 heart failure drug, ouabain, shows potential antitumor activities in lung adenocarcinoma by uniquely

129 ytotoxic effects on tumor cells in vitro and antitumor activities in preclinical studies in vivo, onl

130 ts a promising approach in oncology, showing antitumor activities in various cancers.

131 ared to ACT with IL-2, resulting in superior antitumor activity in a B16-F10 murine melanoma model.

132 SRC inhibitors exhibit potent antitumor activity in a DLC1-positive transgenic cancer

133 tate-specific antigen response rates suggest antitumor activity in a patient subset.

134 imab, 2B8T2M exhibits significantly stronger antitumor activity in a xenograft SCID mouse model and d

135 1F5hIgG1 had good antitumor activity in all tumor models tested.

136 D9 bromodomain cellular function and display antitumor activity in an AML xenograft model.

137 e-2-carboxylic acid (43d), showing promising antitumor activity in breast cancer mice xenograft model

138 Furthermore, borussertib displayed antitumor activity in combination with the MEK inhibitor

139 covalent-allosteric AKT inhibitor, displays antitumor activity in combination with the MEK inhibitor

140 Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients wi

141 kinetic profile with encouraging preliminary antitumor activity in heavily pretreated patients with m

142 ylase (HDAC) inhibition has shown remarkable antitumor activity in hematological malignancies, it has

143 f MM-302 and trastuzumab induced synergistic antitumor activity in HER2-overexpressing xenograft mode

144 ispecific T-cell engagers (BITEs) have shown antitumor activity in humans for CD19-positive malignanc

145 ADCs had greater antitumor activity in immunocompetent versus immunodefic

146 a novel STAT3 inhibitor demonstrating potent antitumor activity in in vitro and in vivo human colorec

147 Noticeably, XWL-1-48 exerted potent antitumor activity in in vitro and in vivo human hepatoc

148 ced the ability of ERK inhibitors to mediate antitumor activity in KRAS-driven PDAC.

149 ion of MK-1775 and Ex527 induces cooperative antitumor activity in lung cancer xenograft model in viv

150 ine whether the MMP12 CTD contributes to its antitumor activity in lung cancer.

151 thways has shown meaningful, but incomplete, antitumor activity in lymphoma.

152 mmune checkpoint blockade results in durable antitumor activity in many advanced malignancies.

153 Purpose Pembrolizumab provides durable antitumor activity in metastatic melanoma, including com

154 Importantly, this antitumor activity in mice was eliminated following macr

155 umor, and it does not interfere with Doxil's antitumor activity in mice.

156 er, the Her2 x CD3 BsAb shows potent in vivo antitumor activity in mouse Her2(2+) and Her2(1+) xenogr

157 olecules that bind/inhibit Skp2 have in vivo antitumor activity in mouse tumors and human patient-der

158 h slow dissociation kinetics and significant antitumor activity in multiple syngeneic tumor models.

159 c9A(+) dendritic cells (DC) displayed strong antitumor activity in murine melanoma, breast carcinoma,

160 Thus, inhibition of HR enhances antitumor activity in otherwise HR-proficient sensitive

161 nvatinib plus pembrolizumab showed promising antitumor activity in patients with advanced endometrial

162 Cabozantinib has antitumor activity in patients with advanced Ewing sarco

163 Rucaparib has antitumor activity in patients with mCRPC and a deleteri

164 I/T/DIN/GM-CSF has significant antitumor activity in patients with relapsed/refractory

165 ed a manageable safety profile and promising antitumor activity in patients with selected solid tumor

166 TR and WEE1 inhibitors demonstrate effective antitumor activity in preclinical models of DLBCL associ

167 Parsaclisib has demonstrated antitumor activity in relapsed or refractory B-cell NHL

168 ntigen-specific lymphocytes has demonstrated antitumor activity in selected patients.

169 ble and manageable safety profile and showed antitumor activity in several tumor types, including FGF

170 PD-1 blockade has produced significant antitumor activity in solid tumors, and similar evidence

171 trafficking through a CAR design for maximal antitumor activity in solid tumors.

172 ive cancer because AKT inhibition has potent antitumor activity in the DLC1-positive transgenic cance

173 Orally administered, 31 achieves significant antitumor activity in the MV4;11 leukemia and MDA-MB-231

174 An antagonistic anti-CCR4 antibody had antitumor activity in the RENCA mouse model of RCC.

175 noma cell line SK-MEL-2 but showed only weak antitumor activity in the SK-MEL-2 human melanoma xenogr

176 hway, which results in T-cell activation and antitumor activity in tumor models.

177 intratumoral T(reg) cells and enhancement of antitumor activity in tumor-infiltrating lymphocytes wit

178 al was designed to evaluate targeted therapy antitumor activity in underexplored cancer types.

179 ed that (19)F-FCP, like carboplatin, retains antitumor activity in various cell lines.

180 The product promoted a potent antitumor activity in various mouse models of cancer wit

181 drug of triptolide, was shown to have potent antitumor activity in various preclinical cancer models.

182 checkpoint were shown to display impressive antitumor activity in various solid or hematological mal

183 -5083), was developed and demonstrated broad antitumor activity in various tumor models.

184 diols and their keto derivatives showed high antitumor activity in vitro against Hek293, Jurkat, K562

185 This BTC demonstrated potent antitumor activity in vivo but was poorly tolerated, whi

186 maintained normal functions and had enhanced antitumor activity in vivo, as well as improved overall

187 human colon cancer cells, but also improved antitumor activity in vivo.

188 on results in potent, dose-dependent in vivo antitumor activity in xenograft models.

189 expression (CVX-8) was used to test in vivo antitumor activity in xenografts models.

190 anoma B16F10 xenograft model to validate its antitumor activity, in comparison with reference ABT-751

191 carbon metabolism of macrophages that enable antitumor activity, including engulfment of CD47(+) canc

192 sistant tumors, PS-1001 resulted in enhanced antitumor activity, increased infiltration of macrophage

193 t a long-lived phenotype exhibiting improved antitumor activities into T-cells by transfecting them w

194 To investigate whether the antitumor activity is due to the predicted mechanism of

195 ll killing in clinic, but the basis of their antitumor activity is not fully understood.

196 vious studies demonstrated that IL-12-driven antitumor activity is short-circuited by a rapid switch

197 drugs with antiviral, immunosuppressive and antitumor activities, its physiological mechanisms of re

198 f cereblon modulator 3 (CC-885), with potent antitumor activity mediated through the degradation of G

199 The encouraging antitumor activity observed in patients with TP53-mutate

200 y influence the development, maturation, and antitumor activities of immune cells.

201 irect protein target for the teratogenic and antitumor activities of immunomodulatory drugs such as t

202 Here we review antitumor activities of innate immune cells, mechanisms

203 cancer cells, focusing on both protumor and antitumor activities of neutrophils at different stages

204 We have reported the antitumor activities of phenformin to enhance the effica

205 GM-CSF-IRF5 axis as a critical driver of the antitumor activities of this versatile cell type.

206 The antitumor activity of (67)Cu-CuSarTATE in the AR42J tumo

207 Furthermore, cGAMP improved the antitumor activity of 5-FU, and clearly reduced the toxi

208 Furthermore, antitumor activity of a chemotherapeutic agent (doxorubi

209 DX3 in sarcoma cells, and to investigate the antitumor activity of a novel small molecule DDX3 inhibi

210 vaccine treatments consistently negated the antitumor activity of a selective BRAF inhibitor in tumo

211 In this study, we tested the antitumor activity of a unique RIG-I agonist, stem loop

212 TR-214 may have the potential to improve the antitumor activity of ACT in humans through increased in

213 ) IIB is an absolute requirement for in vivo antitumor activity of agonistic mouse anti-CD40 monoclon

214 evelop a combination strategy to enhance the antitumor activity of ALK inhibitor monotherapy in human

215 NIVO1+IPI3 provided the greatest antitumor activity of all regimens, with a manageable sa

216 zation of IL1beta significantly enhanced the antitumor activity of alpha-PD-1 and was accompanied by

217 We describe the design, synthesis, and antitumor activity of an 18 carbon alpha,omega-dicarboxy

218 Lack of Tmem176b enhances the antitumor activity of anti-CTLA-4 antibodies through mec

219 tor, we demonstrate that AT-RvDs mediate the antitumor activity of aspirin.

220 Here, we report selective antitumor activity of ATR and WEE1 inhibitors in a subse

221 Purpose We assessed the safety and antitumor activity of avelumab, a fully human anti-progr

222 proteasome inhibition significantly enhanced antitumor activity of bevacizumab, highlighting the impo

223 ll-mediated tumor control and reinforces the antitumor activity of both anti-CTLA-4 and anti-PD-1 ant

224 The antitumor activity of bromodomain and extraterminal moti

225 ce CAR T cell activity and mediate increased antitumor activity of CAR T cells.

226 ion chimeric antigen receptor (CAR) improved antitumor activity of CAR-T cells.

227 ition of L-MDSC was associated with enhanced antitumor activity of CAR-T.

228 The costimulation and antitumor activity of CD27 agonistic Abs have been well

229 proliferation, cytokine production, and the antitumor activity of CD8(+) T cells upon antigenic stim

230 ave been explored as a means of boosting the antitumor activity of chimeric antigen receptor (CAR) T

231 In this study, we examined the antitumor activity of CMLD-2, a small-molecule inhibitor

232 nt intratumoral retention that increased the antitumor activity of coadministered temozolomide (TMZ).

233 Both carriers retained antitumor activity of DAS and could form mixed micelles

234 f BRAF or PI3K significantly potentiated the antitumor activity of degrader 27, suggesting that the c

235 ignificantly and synergistically enhance the antitumor activity of HDACi in glioblastoma and pancreat

236 alpha(high) phenotype, restoring the in vivo antitumor activity of IFNgamma.

237 that ClpP activation is responsible for the antitumor activity of imipridone ONC201.

238 th factor receptor inhibition may complement antitumor activity of immune checkpoint blockade.

239 pecific antitumor immunity, and enhanced the antitumor activity of immune checkpoint inhibitors.

240 in target for thalidomide teratogenicity and antitumor activity of immunomodulatory drugs (IMiDs).

241 d drugs in clinical oncology is clear if the antitumor activity of MOv18 IgE in these preclinical exp

242 ety, pharmacokinetics, pharmacodynamics, and antitumor activity of oral BGJ398, a selective FGFR1-3 t

243 However, no study thus far has evaluated the antitumor activity of PD-1-selected TILs in vivo In two

244 We evaluated safety and antitumor activity of pembrolizumab, an anti-PD-1 antibo

245 Taken together, our study reveals an antitumor activity of phenformin to promote keratinocyte

246 To enhance the antitumor activity of RG7787, we screened for clinically

247 D-1/PD-L1 immunotherapy and demonstrates the antitumor activity of rimantadine.

248 f vancomycin-sensitive bacteria enhances the antitumor activity of RT, which has important clinical r

249 in immunodeficient mice, suggesting that the antitumor activity of RXDX-106 is, in part, due to the p

250 nnoma allograft was also used to examine the antitumor activity of SFN.

251 the molecular mechanism of action and potent antitumor activity of SY-1365, the first selective CDK7

252 umor responses, suggesting that the impaired antitumor activity of the BRAF inhibitor observed in mic

253 In this work, we studied the antitumor activity of the IL-15 superagonist receptor-li

254 fect on NK cell infiltration might limit the antitumor activity of the inhibitors.

255 g a contribution of the immune system to the antitumor activity of these ADCs.

256 The promising preliminary antitumor activity of this alternative schedule in heavi

257 n tumors attenuate the metabolic fitness and antitumor activity of tumor-infiltrating T lymphocytes (

258 macokinetics, pharmacodynamics, and clinical antitumor activity of varlilumab.

259 It has antitumor activities, particularly against pancreatic ca

260 However, antitumor activity, particularly in the context of progr

261 ibitor, 3d (20 mg/kg) potentiated paclitaxel antitumor activity (percentage tumor growth inhibition,

262 y studies demonstrated that (19)F-FCP has an antitumor activity profile similar to that of the parent

263 SR-717 displayed antitumor activity; promoted the activation of CD8(+) T,

264 and refractory tumors, but the durability of antitumor activity requires in vivo persistence.

265 tion of CD4(+) and CD8(+) T cells to CTL and antitumor activity, respectively, was elucidated.

266 Antitumor activity (seven partial responses [six confirm

267 s, cancer cell line cytotoxicity and in vivo antitumor activity, structure-activity relationships, me

268 Intravenously injected monocytes displayed antitumor activity superior to DC vaccines in several ca

269 A2-targeted liposomal prodrug showed greater antitumor activity than 10 mg/kg of docetaxel in A549 no

270 35 with systemic anti-PD-1 generates greater antitumor activity than each respective monotherapy.

271 /kg (qwx3), o(LA)(8)-PTX-PM (50%) has higher antitumor activity than o(LA)(8)-PTX-PM (10%) and PTX-PM

272 nsequently, T9 CAR-T cells mediate a greater antitumor activity than T1 CAR-T cells against establish

273 In vivo, 15 showed more efficacious antitumor activity than the corresponding drug combinati

274 lay low proliferative responses and impaired antitumor activity that can be partially restored by ant

275 t physicochemical properties and significant antitumor activity that supports clinical development.

276 The Ab-sumIL2 significantly enhances antitumor activity through tumor targeting and specific

277 These combined mechanisms imparted potent antitumor activity to 1F5mIgG2a, particularly against th

278 t, compound 14d displayed promising in vitro antitumor activity toward three different prostate cance

279 of safety/tolerability and pharmacokinetics; antitumor activity was a secondary objective.

280 Antitumor activity was also observed in xenograft models

281 Enhanced antitumor activity was associated with a unique tumor cy

282 Antitumor activity was documented.

283 The antitumor activity was evaluated, showing that treatment

284 basic side chains, but the greatest in vivo antitumor activity was found for compounds containing a

285 Using genetic and pharmacologic approaches, antitumor activity was seen with Skp2 loss or inhibition

286 aximum-tolerated dose (MTD), and preliminary antitumor activity were evaluated.

287 rofiles, high target specificity, and robust antitumor activity were observed in these models after a

288 Signs of single-agent antitumor activity were observed: 1 unconfirmed partial

289 D-1 expression in B7-H3.CAR-Ts, and superior antitumor activity when targeting tumor cells that const

290 in a mouse syngeneic model demonstrated high antitumor activity which significantly reduced the tumor

291 b provided clinically meaningful and durable antitumor activity with a manageable safety profile.

292 Ipilimumab and nivolumab demonstrated antitumor activity with acceptable toxicity in patients

293 checkpoint or CSF1R blockade caused additive antitumor activity with complete tumor regressions in so

294 Pembrolizumab demonstrated significant antitumor activity with durable responses and a favorabl

295 sponse rate primary end point, demonstrating antitumor activity with lenvatinib in R/M ACC patients.

296 se it exhibited enhanced (>30-fold) in vitro antitumor activity with respect to DCA and increased in

297 12l showed comparable antitumor activity with the combination medication in MM

298 d CD4(+) T cells were necessary for enhanced antitumor activity, with elevated numbers of activated C

299 ta indicate that the combination has greater antitumor activity without additional safety concerns ve

300 me inhibitor not only possesses an effective antitumor activity without causing any ill effects to an